R
Romulus Capital Management, LLC
+ HältHIND
+0.00%
3-Monats-Rendite
$1.600
-0.029 (-1.84%)Zum Schluss
Loading chart…
- Hoch
- 1.660
- Eröffnung
- 1.660
- Volumengewichteter Durchschnittskurs
- 1.61
- Volumen
- 19.77K
- Marktkap.
- —
- Tief
- 1.570
- Umsatz
- 31.83K
- EV/EBITDA, TTM
- -0.56
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
KI-Analyse of Vyome Holdings Inc (HIND)
HaltenCurrently, Vyome Holdings Inc (HIND) is not a good buy due to its extremely low RSI of 17.286, indicating oversold conditions, and a significant year-to-date change of -54.93%. While the analyst target suggests potential upside, the current financial instability and negative earnings reports raise concerns.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Vyome Holdings Inc (HIND) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -8.15.
Whales, die HIND halten
Event-Zeitleiste
News
5.009-14NewsfilterVyome Holdings Appoints New CFO Jerry Leonard
9.505-29seekingalphaVyome Holdings Reports Q1 Revenue of $31.59M
- 7.505-28Newsfilter
Vyome Partners with Impetis for JAK Inhibitors, Targeting $57B Market
- 9.503-26seekingalpha
Vyome Holdings Reports FY 2025 Financial Results
- 8.502-18Newsfilter
Vyome Publishes Preclinical Data for VT-1908
HIND FAQ – beantwortet von Alphio AI
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology. It operates in the Healthcare sector.
Currently, Vyome Holdings Inc (HIND) is not a good buy due to its extremely low RSI of 17.286, indicating oversold conditions, and a significant year-to-date change of -54.93%. While the analyst target suggests potential upside, the current financial instability and negative earnings reports raise concerns.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.